Aerie Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of ophthalmic diseases. It focuses on the development of products for the pharmaceutical treatment of glaucoma. The Company’s lead product candidate, AR-13324, is the first of a new dual action drug class that reduces the eye’s fluid inflow while also increasing fluid outflow through the trabecular meshwork, which is the eye’s main fluid drain, all in a highly effective single drop per day. Aerie’s PG324 fixed combination of AR-13324 with latanoprost is a first-in-class glaucoma therapy to lower intraocular pressure by reducing fluid inflow while also opening both of the eye’s fluid drains. This product candidate offers the convenience of two drugs in one eye drop.

Type
Public
HQ
Irvine, US
Founded
2005
Size (employees)
95 (est)+36%
Aerie Pharmaceuticals was founded in 2005 and is headquartered in Irvine, US
Report incorrect company information

Key People/Management at Aerie Pharmaceuticals

Richard J. Rubino

Richard J. Rubino

Chief Financial Officer
Casey C. Kopczynski

Casey C. Kopczynski

Chief Research Officer and Co-Founder
Thomas A. Mitro

Thomas A. Mitro

President and Chief Operating Officer
Gerald D. Cagle

Gerald D. Cagle

Independent Director
Murray Goldberg

Murray Goldberg

Member of the Board of Directors

Aerie Pharmaceuticals Office Locations

Aerie Pharmaceuticals has offices in Bedminster Township, Irvine, Dublin and Durham
Irvine, US (HQ)
2030 Main St
Bedminster Township, US
135 US-206
Durham, US
4301 Emperor Blvd
Dublin, IE
28-32 Pembroke Street
Show all (4)
Report incorrect company information

Aerie Pharmaceuticals Financials and Metrics

Aerie Pharmaceuticals Financials

USD

Net income (FY, 2017)

(145.1 m)

EBIT (FY, 2017)

(145.7 m)

Market capitalization (18-Apr-2018)

1.9 b

Cash (31-Dec-2017)

197.6 m
Aerie Pharmaceuticals's current market capitalization is $1.9 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

44.5 m73.6 m

R&D expense

52.4 m72.1 m

Operating expense total

96.9 m145.7 m

EBIT

(96.9 m)(145.7 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

General and administrative expense

7.5 m7.5 m9.8 m9.4 m10.6 m

R&D expense

10.6 m9.9 m12.3 m13.3 m12.7 m

Operating expense total

18.1 m17.4 m22.1 m22.7 m23.3 m

EBIT

(18.1 m)(17.4 m)(22.1 m)(22.7 m)(23.3 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

69.6 m85.6 m91.1 m197.9 m197.6 m

Accounts Receivable

399 m

Inventories

618 k1.1 m1.9 m4 m

Current Assets

70.3 m141 m138.4 m237.7 m254.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Cash

4.6 m35.8 m27.9 m148.9 m113.5 m100.9 m106.9 m74.3 m58.5 m211.9 m

Current Assets

7.1 m65.8 m57.3 m171.7 m171 m159.9 m156.6 m120.7 m108.2 m256.5 m

Total Assets

7.2 m66 m57.7 m173.3 m195.2 m176.3 m175.2 m139.2 m120.1 m265.9 m

Accounts Payable

3.2 m3.7 m4.8 m7 m21.9 m17.7 m18 m15.5 m13.6 m13.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(31.1 m)(48.1 m)(74.4 m)(99.1 m)(145.1 m)

Depreciation and Amortization

64 k73 k252 k970 k1.4 m

Accounts Payable

2 m551 k

Cash From Operating Activities

(16.4 m)(33.7 m)(55.7 m)(79.8 m)(93.2 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016

Net Income

(20.9 m)(6.7 m)(18.5 m)(31.6 m)(17.2 m)(36 m)(54 m)(22.7 m)(45.9 m)(69.7 m)

Depreciation and Amortization

47 k15 k31 k50 k24 k60 k102 k223 k457 k702 k

Accounts Payable

1 m208 k1.4 m2.3 m(12 k)(6 k)2.4 m(6 k)(6 k)

Cash From Operating Activities

(11.6 m)(4.5 m)(12.9 m)(22.4 m)(13.3 m)(29.6 m)(41.5 m)(19.4 m)(39.8 m)(61 m)
USDY, 2017

Financial Leverage

2.1 x
Show all financial metrics
Report incorrect company information